Life expectancy in multiple sclerosis by EDSS score.
Expanded disability status scale
Life expectancy
Mortality
Multiple sclerosis
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
06
07
2022
revised:
24
09
2022
accepted:
04
10
2022
pubmed:
17
10
2022
medline:
15
12
2022
entrez:
16
10
2022
Statut:
ppublish
Résumé
The median survival time of newly-diagnosed MS patients without severe disabilities is approximately 30-35 years. The prognosis after the onset of severe disability has not been reported. Based on Harding et al.'s 2018 study of the Southeast Wales MS registry, we calculated life expectancies according to the Expanded Disability Status Scale (EDSS). Upon loss of independent ambulation (EDSS 6-6.5; mean age 51.2) life expectancy was 13.3 additional years. At EDSS 9-9.5 (mean age 70.8) life expectancy was 1.1 additional years. These figures provide an empirical basis for discussions of advanced MS care planning.
Identifiants
pubmed: 36244189
pii: S2211-0348(22)00724-6
doi: 10.1016/j.msard.2022.104219
pii:
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
104219Subventions
Organisme : Medical Research Council
ID : MR/L010305/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declarations of Competing Interest Lucas Walz has no conflicts of interest. Jordan Brooks and Robert Shavelle have served as expert witnesses on life expectancy for persons with neurological disabilities including some with multiple sclerosis. Neil Robertson has received honoraria and/or support to attend educational meetings from Biogen, Novartis, Genzyme, Teva, Roche. His research group has also received research support from Biogen, Novartis and Genzyme. Katharine Harding has received honoraria and/or support to attend educational meetings from Biogen, Novartis, Merck Serono, and Roche.